OncRef

Clinical Trial: NCT06211036

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 3

Lead Sponsor:Amgen
Information Provided By:Amgen
Last Update Posted:2026-11-06

Study Overview

Brief Summary

The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).

Official Title

A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305)

Conditions

Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer

Intervention / Treatment

  • Drug: Tarlatamab
  • Drug: Durvalumab

Other Study ID Numbers

  • 20200041
  • 2023-505989-29
  • 2023

Start Date (Actual)

2024-06-05

Primary Completion Date (Estimated)

2030-04-02

Study Completion Date (Estimated)

2030-04-02

Enrollment (Actual)

563

Study Type

Interventional

Phase

Phase 3